Glaucoma News and Research

Latest Glaucoma News and Research

Some top researchers no longer think of glaucoma solely as an eye disease

A new paradigm to explain glaucoma is rapidly emerging, and it is generating brain-based treatment advances that may ultimately vanquish the disease known as the "sneak thief of sight." A review now available in Ophthalmology, the journal of the American Academy of Ophthalmology, reports that some top researchers no longer think of glaucoma solely as an eye disease.

8 Mar 2012

Intellect Neurosciences receives U.S. patent allowance for ANTISENILIN to treat AD

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases announced today that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent claims covering the company's ANTISENILIN monoclonal antibody platform technology for the treatment and prevention of Alzheimer's disease.

7 Mar 2012

Ivantis initiates enrollment in Hydrus Microstent study for open angle glaucoma

Ivantis announced the enrollment of the first patient in the Hydrus IV study today. The Hydrus Microstent is the world's first intracanalicular scaffold for treatment of primary open angle glaucoma, a disease that afflicts over 70 million people worldwide and approximately 3 million people in the United States.

6 Mar 2012

ACADIA, Allergan extend drug discovery collaboration

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it has extended its drug discovery and development collaboration with Allergan, Inc..

5 Mar 2012

Photon etc. announces the launch of IRIS, an innovative Retinal Hyperspectral Imaging system

Targeting the emergent field of hyperspectral retinal imaging, Photon etc. is proud to launch IRIS™, a new device for non-invasive localization of biomolecules in the eye fundus. Based on a custom-made mydriatic retinal camera and Photon etc.’s Tunable Laser Source, IRIS™ is a versatile instrument that allows high definition retinal imaging at any wavelength from 420 to 1000 nm. IRIS™ is the ideal research tool to better understand and develop tomorrow’s treatments for retinal diseases, such as diabetic retinopathy and age-related macular degeneration. This product is sold for research purposes only.

1 Mar 2012

Viewpoints: Disabled 'disdain' a poisonous meme? Two sides on physician payments issue, letting Mich.'s community colleges train nurses

Disability advocates across the political spectrum strongly supported the 2010 health care reform. They had obvious reasons to do so. The new law provides protections for people with preexisting conditions, regulations to make sure insurers properly cover care for chronic illnesses and expanded coverage for young adults and low-income families. But more is at stake here than factual inaccuracies.

28 Feb 2012

Dompé enters definitive agreement to acquire Anabasis

Dompé, one of Italy's leading biopharmaceutical companies, announced today that it has entered into a definitive agreement to acquire 100% of Anabasis Srl, a privately held Italian research and development biopharmaceutical company, focused on ocular diseases.

28 Feb 2012

Can-Fite receives FDA Orphan Drug Status for CF102 to treat hepatocellular carcinoma

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, and liver diseases, traded on the Tel Aviv Stock Exchange, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Status for its drug candidate, CF102, for the treatment of hepatocellular carcinoma.

23 Feb 2012

Mobius selects The Apothecary Shops as distribution partner for Mitosol Kit for Ophthalmic Use

Apothecary Shop Wholesale, Inc., an affiliate of The Apothecary Shops Specialty Pharmacies, has received exclusive distribution rights from Mobius Therapeutics, LLC for its new drug Mitosol (mitomycin for solution) 0.2 mg/vial Kit for Ophthalmic Use.

18 Feb 2012

FDA approves preservative-free drug for glaucoma

The U.S. Food and Drugs Administration (FDA) has approved tafluprost ophthalmic solution (Zioptan, Merck) 0.0015%, the first preservative-free prostaglandin analog ophthalmic solution for glaucoma.

15 Feb 2012

HB-EGF plays a critical role during retina regeneration

University of Michigan Health System research into the mechanisms by which zebrafish are able to regenerate damaged retinas after injury suggests new strategies for one day being able to do the same in humans - potentially allowing doctors to slow or reverse conditions like macular degeneration and glaucoma.

15 Feb 2012

Aganirsen demonstrates significant activity in two models of wet AMD, ischemic retinopathy

Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, today announced the publication of data demonstrating the significant activity of aganirsen (GS-101, eye drops) in two important models of retinal neovascular disease, wet age-related macular degeneration (AMD) and ischemic retinopathy.

15 Feb 2012

Merck's ZIOPTAN for reducing elevated IOP receives FDA approval

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration has approved ZIOPTANTM (tafluprost ophthalmic solution) 0.0015%, the first preservative-free prostaglandin analog ophthalmic solution.

13 Feb 2012

Bexarotene appears to help clear out excess plaque in Alzheimer's

"In the last eight days, scientists have delivered a powerful one-two punch in the fight to defeat Alzheimer's disease," said Stacy Pagos Haller, President and CEO of the American Health Assistance Foundation (AHAF), a nonprofit that identifies and funds exceptionally high-impact research worldwide through its Alzheimer's Disease Research program.

13 Feb 2012

Grand Challenges Canada announces 15 grants to support rising stars in global health

Grand Challenges Canada today announced 15 grants valued in total at more than $1.5 million awarded to some of Canada's most creative innovators from across the country in support of their work to improve global health conditions.

10 Feb 2012

Two different research groups make similar advances in AD study

Two different research groups have independently made the same important discoveries on how Alzheimer's disease spreads in the brain, according to a February 2 New York Times story. The groups' findings have the potential to give us a much more sophisticated understanding of what goes wrong in Alzheimer's disease and, more importantly, what can be done to prevent or repair damage in the brain.

4 Feb 2012

UH vision scientist hopes techniques lead to earlier diagnoses in glaucoma

A University of Houston (UH) vision scientist has received a $1.85 million grant from the National Institutes of Health (NIH) to investigate whether his techniques are more effective than others in understanding the earliest changes of glaucoma, which could lead to developing a way to earlier diagnose this potentially blinding disease.

27 Jan 2012

Montefiore vision experts encourage public to learn more about glaucoma

January is National Glaucoma Awareness Month. Vision experts at Montefiore Medical Center encourage the public to learn more about this disease, which is the leading cause of preventable blindness in the United States.

24 Jan 2012

RPB awards $220,000 to SUNY Downstate for eye research

Capping SUNY Downstate Medical Center's growth into a major center for eye research, Research to Prevent Blindness (RPB) has awarded SUNY Downstate a four-year challenge grant of $220,000 to spur the development of advanced research into the causes, treatment, and prevention of blinding diseases. Douglas R. Lazzaro, MD, professor and chair of ophthalmology, is the principal investigator.

24 Jan 2012

SSRI use raises risk of fall among elderly with dementia: Study

A new study reveals that nursing home residents with dementia who use selective serotonin reuptake inhibitors (SSRIs) have an increased risk of having a fall that causes injury compared with those who do not use SSRIs. Additionally those using average doses have 3 times the risk compared with nonusers, the authors, led by Carolyn S. Sterke, from Erasmus University Medical Center, Rotterdam, the Netherlands, report. Authors write, “Even at low doses, SSRIs are associated with increased risk of an injurious fall in nursing home residents with dementia.”

22 Jan 2012

Glaucoma News and Research

Latest Glaucoma News and Research

Some top researchers no longer think of glaucoma solely as an eye disease

Intellect Neurosciences receives U.S. patent allowance for ANTISENILIN to treat AD

Ivantis initiates enrollment in Hydrus Microstent study for open angle glaucoma

ACADIA, Allergan extend drug discovery collaboration

Photon etc. announces the launch of IRIS, an innovative Retinal Hyperspectral Imaging system

Viewpoints: Disabled 'disdain' a poisonous meme? Two sides on physician payments issue, letting Mich.'s community colleges train nurses

Dompé enters definitive agreement to acquire Anabasis

Can-Fite receives FDA Orphan Drug Status for CF102 to treat hepatocellular carcinoma

Mobius selects The Apothecary Shops as distribution partner for Mitosol Kit for Ophthalmic Use

FDA approves preservative-free drug for glaucoma

HB-EGF plays a critical role during retina regeneration

Aganirsen demonstrates significant activity in two models of wet AMD, ischemic retinopathy

Merck's ZIOPTAN for reducing elevated IOP receives FDA approval

Bexarotene appears to help clear out excess plaque in Alzheimer's

Grand Challenges Canada announces 15 grants to support rising stars in global health

Two different research groups make similar advances in AD study

UH vision scientist hopes techniques lead to earlier diagnoses in glaucoma

Montefiore vision experts encourage public to learn more about glaucoma

RPB awards $220,000 to SUNY Downstate for eye research

SSRI use raises risk of fall among elderly with dementia: Study

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Glaucoma News and Research

Latest Glaucoma News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in